Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Provectus Biopharmaceuticals and its subsidiary VisiRose announced the issuance of U.S. Patent No. 12,661,335 for a light-independent rose bengal sodium formulation targeting drug-resistant Gram-positive bacteria like MRSA. The patent covers a topical eye drop that kills bacteria and eradicates biofilms without requiring light activation, potentially enabling a self-administered treatment profile similar to standard antibiotics.
Key figures
- Ph range
- 6.5 to 7.6
- Patent number
- 12,661,335
- Us application number
- 18/089,134
- Concentration range ug ml
- 0.2 to 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.